Decreased frequency of peripheral CD4 +CD161 + Th 17-precursor cells in kidney transplant recipients on long-term therapy with Belatacept

Transplant International

Volumn 25, Issue 4, 2012, Pages 455-463

  Vondran, Florian Wolfgang Rudolf ^a   Timrott, Kai ^a   Kollrich, Sonja ^a   Klempnauer, Juergen ^a   Schwinzer, Reinhard ^a   Becker, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Belatacept; CD4 +CD161 +; kidney; soluble CD30; Th 17; transplantation

Indexed keywords

BASILIXIMAB; BELATACEPT; CD161 ANTIGEN; CD30 ANTIGEN; INTERLEUKIN 17; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LONG TERM CARE; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH17 CELL;

ADULT; AGED; ANTIGENS, CD4; CALCINEURIN; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; KIDNEY TRANSPLANTATION; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; TH17 CELLS;

EID: 84858444074     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01441.x     Document Type: Article

References (43)

1. Hawksworth JS, Leeser D, Jindal RM, Falta E, Tadaki D, Elster EA,. New directions for induction immunosuppression strategy in solid organ transplantation. Am J Surg 2009; 197: 515.
2. Yabu JM, Vincenti F,. Kidney transplantation: the ideal immunosuppression regimen. Adv Chronic Kidney Dis 2009; 16: 226.
3. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B,. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
4. Merville P,. Combating chronic renal allograft dysfunction: optimal immunosuppressive regimens. Drugs 2005; 65: 615.
5. Li C, Yang CW,. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009; 5: 513.
6. Opelz G, Dohler B,. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007; 84: 137.
7. Sprangers B, Kuypers DR, Vanrenterghem Y,. Immunosuppression: does one regimen fit all? Transplantation 2011; 92: 251.
8. Gaston RS,. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009; 4: 2029.
9. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
10. Rietz C, Chen L,. New B7 family members with positive and negative costimulatory function. Am J Transplant 2004; 4: 8.
11. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
12. Emamaullee J, Toso C, Merani S, Shapiro AM,. Costimulatory blockade with belatacept in clinical and experimental transplantationâa review. Expert Opin Biol Ther 2009; 9: 789.
13. Chavez H, Beaudreuil S, Abbed K, et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007; 17: 243.
14. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086.
15. Wood KJ, Sakaguchi S,. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199.
16. Jiang S, Lechler RI, He XS, Huang JF,. Regulatory T cells and transplantation tolerance. Hum Immunol 2006; 67: 765.
17. Harrington LE, Mangan PR, Weaver CT,. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006; 18: 349.
18. Crome SQ, Wang AY, Levings MK,. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 2010; 159: 109.
19. Cosmi L, De Palma R, Santarlasci V, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008; 205: 1903.
20. Romagnani S, Maggi E, Liotta F, Cosmi L, Annunziato F,. Properties and origin of human Th17 cells. Mol Immunol 2009; 47: 3.
21. Mitchell P, Afzali B, Lombardi G, Lechler RI,. The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr Opin Organ Transplant 2009; 14: 326.
22. Heidt S, San D, Chadha R, Wood KJ,. The impact of Th17 cells on transplant rejection and the induction of tolerance. Curr Opin Organ Transplant 2010; 15: 456.
23. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I,. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340.
24. Itoh S, Kimura N, Axtell RC, et al. Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion. Circulation 2011; 124: S187.
25. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
26. Vondran FW, Timrott K, Tross J, et al. Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation. Transpl Int 2010; 23: 514.
27. Saini D, Ramachandran S, Nataraju A, et al. Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection. Am J Transplant 2008; 8: 1798.
28. Kamali K, Abbasi MA, Farokhi B, et al. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection. Exp Clin Transplant 2009; 7: 237.
29. Pavlova Y, Viklicky O, Slatinska J, et al. Soluble CD30 and hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft. Transpl Immunol 2011; 25: 72.
30. Susal C, Dohler B, Sadeghi M, et al. Posttransplant sCD30 as a predictor of kidney graft outcome. Transplantation 2011; 91: 1364.
31. Gilfillan MC, Noel PJ, Podack ER, Reiner SL, Thompson CB,. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998; 160: 2180.
32. Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM,. IL-2-independent activation and proliferation in human T cells induced by CD28. J Immunol 1999; 163: 1809.
33. Bram RJ, Hung DT, Martin PK, Schreiber SL, Crabtree GR,. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 1993; 13: 4760.
34. Wiley SR, Goodwin RG, Smith CA,. Reverse signaling via CD30 ligand. J Immunol 1996; 157: 3635.
35. Golovina TN, Mikheeva T, Suhoski MM, et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008; 181: 2855.
36. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009; 183: 2475.
37. Furuzawa-Carballeda J, Lima G, Uribe-Uribe N, et al. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. Transplant Proc 2010; 42: 3489.
38. Bouguermouh S, Fortin G, Baba N, Rubio M, Sarfati M,. CD28 co-stimulation down regulates Th17 development. PLoS ONE 2009; 4: e5087.
39. Baeten D, Louis S, Braud C, et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006; 17: 294.
40. Pallier A, Hillion S, Danger R, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78: 503.
41. Turka LA, Wood K, Bluestone JA,. Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the establishment of tolerance consortia. Curr Opin Organ Transplant 2010; 15: 441.
42. Morteau O, Blundell S, Chakera A, et al. Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo. PLoS ONE 2010; 5: e13294.
43. Vincenti F, Dritselis A, Kirkpatrick P,. Belatacept. Nat Rev Drug Discov 2011; 10: 655.